ClearPoint Neuro, Inc. (CLPT): Price and Financial Metrics

ClearPoint Neuro, Inc. (CLPT): $5.87

0.34 (-5.48%)

POWR Rating

Component Grades

Momentum

F

Stability

C

Sentiment

Quality

D

CLPT Price/Volume Stats

Current price $5.87 52-week high $8.37
Prev. close $6.21 52-week low $4.05
Day low $5.80 Volume 149,900
Day high $6.26 Avg. volume 143,586
50-day MA $6.09 Dividend yield N/A
200-day MA $6.07 Market Cap 160.96M

CLPT Stock Price Chart Interactive Chart >


ClearPoint Neuro, Inc. (CLPT) Company Bio


ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.


CLPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CLPT Latest Social Stream


Loading social stream, please wait...

View Full CLPT Social Stream

Latest CLPT News From Around the Web

Below are the latest news stories about CLEARPOINT NEURO INC that investors may wish to consider to help them evaluate CLPT as an investment opportunity.

Those who invested in ClearPoint Neuro (NASDAQ:CLPT) five years ago are up 365%

Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...

Yahoo | December 19, 2023

7 Solid Small-Caps for 2024 and Beyond

Small-cap stocks are positioned to beat the biggest companies in 2024 as risk tolerance climbs and shares remain undervalued

Jeremy Flint on InvestorPlace | December 5, 2023

Are Investors Undervaluing ClearPoint Neuro, Inc. (NASDAQ:CLPT) By 41%?

Key Insights The projected fair value for ClearPoint Neuro is US$10.08 based on 2 Stage Free Cash Flow to Equity...

Yahoo | November 22, 2023

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2023 Earnings Call Transcript November 9, 2023 ClearPoint Neuro, Inc. beats earnings expectations. Reported EPS is $-0.0002, expectations were $-0.25. Operator: Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call. Comments made on this call may include statements that are forward-looking within […]

Yahoo | November 10, 2023

ClearPoint Neuro Reports Third Quarter 2023 Results

Biologics & Drug Delivery Growing 55%; Q3 Operational Cash Burn of $1.8MSOLANA BEACH, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its third quarter ended September 30, 2023. Third Quarter Highlights Reported quarterly revenue of $5.8 million, a 12% year-over-year increase;Increased biologics and drug delivery revenue

Yahoo | November 9, 2023

Read More 'CLPT' Stories Here

CLPT Price Returns

1-mo 10.55%
3-mo -19.26%
6-mo 2.98%
1-year -26.26%
3-year -67.11%
5-year 80.06%
YTD -13.55%
2023 -19.83%
2022 -24.51%
2021 -29.39%
2020 231.04%
2019 205.73%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!